The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of combined treatment with sipuleucel-T and IL-15 on tumor control, tumor-infiltrating immune effectors, and key mediators of immunoresistance in a preclinical prostate cancer model.
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Pfizer/EMD Serono; Sanofi; Tolmar Therapeutics
Speakers' Bureau - AstraZeneca; Bayer; Genentech/Roche; Merck; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche
 
Muhammad Azeem Saeed
No Relationships to Disclose
 
Bo Peng
No Relationships to Disclose
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Iterion Therapeutics, Inc; Total Health Conference
Consulting or Advisory Role - Aadi; Acuta Capital Partners, LLC; ADRx; Advenchen Laboratories; Agenus; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Boxer Capital LLC; Curis; Daiihi Sankyo; Deciphera; Deciphera Pharmaceuticals,; EcoR1 Capital; Epizyme; Hinge Bio, Inc.; Intellisphere; Kronos Bio, Inc.; PTC Therapeutics; PTC Therapeutics; Putnam Associates; Race Oncology; Regeneron; Salarius Pharmaceuticals, Inc.,
Research Funding - GlaxoSmithKline; Merck; Pfizer; Polaris; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; Kronos Bio, Inc
 
Nadeem Anwar Sheikh
Employment - Dendreon
 
Todd A. Fehniger
Stock and Other Ownership Interests - Indapta Therapeutics; Orca Bio; WUGEN, Inc.
Consulting or Advisory Role - Affimed Therapeutics; AI proteins; Smart Immune; WUGEN, Inc.
Research Funding - Affimed Therapeutics (Inst); AI proteins (Inst); HCW Biologics (Inst); WUGEN, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Patents filed by my institution where i am listed as a co-inventor, licensed to Wugen, Inc. (Inst)